<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Treatment and prognosis of nonspecific interstitial pneumonia
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Treatment and prognosis of nonspecific interstitial pneumonia
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Treatment and prognosis of nonspecific interstitial pneumonia
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kevin R Flaherty, MD, MS
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Talmadge E King, Jr, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Paul Dieffenbach, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 05, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1635603349">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nonspecific interstitial pneumonia (NSIP) can be idiopathic or can be seen in association with connective tissue disease, HIV infection, a variety of drugs, and hypersensitivity pneumonitis. When idiopathic, NSIP is considered one of the idiopathic interstitial pneumonias (IIPs), which also include usual interstitial pneumonia (UIP)/idiopathic pulmonary fibrosis (IPF), desquamative interstitial pneumonia (DIP), respiratory bronchiolitis-associated interstitial lung disease (RB-ILD), acute interstitial pneumonia (AIP), and cryptogenic organizing pneumonia (COP)  (
         <a class="graphic graphic_table graphicRef95445" href="/z/d/graphic/95445.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid1">
          1
         </a>
         ]. Idiopathic NSIP can present alone or in combination with one of the other IIPs.
        </p>
        <p>
         The treatment and prognosis of NSIP will be reviewed here. The clinical manifestations, evaluation, and diagnosis of NSIP and the diagnosis and management of the other IIPs are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/112195.html" rel="external">
          "Causes, clinical manifestations, evaluation, and diagnosis of nonspecific interstitial pneumonia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4302.html" rel="external">
          "Idiopathic interstitial pneumonias: Classification and pathology"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14870.html" rel="external">
          "Clinical manifestations and diagnosis of idiopathic pulmonary fibrosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4328.html" rel="external">
          "Treatment of idiopathic pulmonary fibrosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4319.html" rel="external">
          "Respiratory bronchiolitis-associated interstitial lung disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4332.html" rel="external">
          "Cryptogenic organizing pneumonia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4369.html" rel="external">
          "Acute interstitial pneumonia (Hamman-Rich syndrome)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h1">
          OVERVIEW OF TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The treatment of NSIP depends on the cause, disease severity, and rate of progression. While the discussion in the sections that follow will emphasize the treatment for idiopathic NSIP, much of the support for treatment selections is based on experience in connective tissue associated NSIP.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Drug or inhalational exposure
         </strong>
         – For patients with NSIP associated with a drug or inhalational exposure, the first step is to remove the inciting exposure. This alone may be adequate treatment. (See
         <a class="medical medical_review" href="/z/d/html/112195.html" rel="external">
          "Causes, clinical manifestations, evaluation, and diagnosis of nonspecific interstitial pneumonia", section on 'Definition'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Connective tissue disease
         </strong>
         – For patients with NSIP complicating a known connective tissue disease (eg, polymyositis/dermatomyositis, rheumatoid arthritis, systemic sclerosis), specific therapies for those diseases may guide treatment of the NSIP. (See
         <a class="medical medical_review" href="/z/d/html/4304.html" rel="external">
          "Interstitial lung disease in dermatomyositis and polymyositis: Clinical manifestations and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4380.html" rel="external">
          "Overview of pleuropulmonary diseases associated with rheumatoid arthritis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4301.html" rel="external">
          "Interstitial lung disease associated with Sjögren's disease: Clinical manifestations, evaluation, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4377.html" rel="external">
          "Overview of pulmonary complications of systemic sclerosis (scleroderma)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3117.html" rel="external">
          "Granulomatosis with polyangiitis and microscopic polyangiitis: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          HIV infection
         </strong>
         – For patients with HIV infection, case reports suggest that NSIP may improve spontaneously [
         <a href="#rid2">
          2
         </a>
         ]. Others have responded to systemic glucocorticoids in combination with antiretroviral therapy (ART). In the absence of more definitive data, a reasonable approach, after careful exclusion of infection (eg,
         <em>
          Pneumocystis jirovecii
         </em>
         ,
         <em>
          Histoplasma
         </em>
         , mycobacteria, cytomegalovirus), is to initiate ART and reserve systemic glucocorticoids for patients who fail to improve [
         <a href="#rid3">
          3,4
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1995991239">
         <span class="h2">
          Supportive care
         </span>
         <span class="headingEndMark">
          —
         </span>
         In terms of supportive care, current smokers should be strongly advised to stop smoking; pneumococcal, coronavirus 2019 (COVID-19), and seasonal influenza vaccination should be offered as appropriate. (See
         <a class="medical medical_review" href="/z/d/html/16634.html" rel="external">
          "Overview of smoking cessation management in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7021.html" rel="external">
          "Pneumococcal vaccination in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/129849.html" rel="external">
          "COVID-19: Vaccines"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7007.html" rel="external">
          "Seasonal influenza vaccination in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1411577868">
         <span class="h1">
          OBSERVATION FOR MILD STABLE DISEASE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some patients with NSIP (less than 20 percent) improve or stabilize without therapy. These patients typically have few symptoms (eg, dyspnea with moderate exertion) and minimal impairment on pulmonary function testing. For these patients, it may be reasonable to defer therapy until there is evidence of disease progression. This approach has not been formally studied and should be limited to patients with mild, stable disease with close follow-up [
         <a href="#rid5">
          5-8
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H141008111">
         <span class="h1">
          INITIAL THERAPY FOR MODERATE TO SEVERE DISEASE
         </span>
         <span class="headingEndMark">
          —
         </span>
         For the majority of patients with NSIP who have moderate symptoms and impairment on pulmonary function testing, and also diffuse abnormalities on high resolution computed tomography (HRCT), we suggest initiation of systemic glucocorticoids. This advice is based on observational data and our clinical experience. As the experience treating NSIP in patients with a known connective tissue disease is greater than for idiopathic NSIP, some of the choices are based on extrapolation.
        </p>
        <p>
         For most such patients, addition of a second immunosuppressive agent is deferred for three to six months, so the response to glucocorticoid therapy can be assessed. However, for patients with more severe initial disease, we often initiate oral glucocorticoids and an additional immunosuppressive agent together. The usual choices for initial therapy are
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         and
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         [
         <a href="#rid5">
          5,8-18
         </a>
         ].
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          Cyclophosphamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         , and calcineurin inhibitors are generally reserved for patients with disease that is refractory to initial therapy. (See
         <a class="local">
          'Refractory disease'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h2">
          Glucocorticoids
         </span>
         <span class="headingEndMark">
          —
         </span>
         The optimal dose and duration of glucocorticoid therapy is not known, and most studies of patients with idiopathic NSIP consist of a small number of patients and a variety of regimens [
         <a href="#rid5">
          5,8-11,13-19
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dose and administration
         </strong>
         – We typically begin with
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         0.5 to 1 mg/kg ideal body weight per day up to a maximum of 60 mg/day for one month followed by 30 to 40 mg/day for an additional two months. Dosing for patients presenting with impending or actual respiratory failure is described below. (See
         <a class="local">
          'Pulse methylprednisolone'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients who respond or stabilize with treatment, the
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         dose is gradually tapered. While the optimal treatment duration is unknown, we aim to reach 5 to 10 mg daily or on alternate days, by the end of six to nine months, with attempted cessation after at least one year of therapy [
         <a href="#rid6">
          6,19
         </a>
         ]. In one series, relapse was associated with shorter duration of therapy (4.7 compared with 7.7 months) [
         <a href="#rid20">
          20
         </a>
         ]. In another series, the average treatment length was 17.4 +/- 12.1 months [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients who relapse when
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         is tapered or discontinued, low-dose prednisone can be maintained for a longer period [
         <a href="#rid10">
          10,20
         </a>
         ]. Or, if relapse occurs at higher prednisone doses, another immunosuppressive agent can be added as a glucocorticoid-sparing agent. (See
         <a class="local">
          'Additional immunosuppressive drugs'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
         – Glucocorticoid treatment is associated with a variety of adverse effects [
         <a href="#rid21">
          21
         </a>
         ]. Thus, careful and ongoing assessment of risks and benefits is essential. (See
         <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">
          "Major adverse effects of systemic glucocorticoids"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <em>
          Pneumocystis jirovecii
         </em>
         pneumonia (PCP) prophylaxis is not routinely recommended for all patients taking glucocorticoids. However, in patients with underlying lung disease such as NSIP, it is reasonable to administer prophylaxis in patients on moderate to high doses of glucocorticoids (eg,
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         20 mg daily and above for &gt;1 month) since PCP could significantly worsen lung function. In addition, it can be difficult to differentiate worsening of underlying NSIP from intercurrent PCP, if the patient experiences worsening symptoms. (See
         <a class="medical medical_review" href="/z/d/html/1393.html" rel="external">
          "Treatment and prevention of Pneumocystis pneumonia in patients without HIV", section on 'Prophylaxis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – A number of case series have described the response to glucocorticoids in NSIP, but no randomized trials have been performed.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Among 35 patients with biopsy-proven NSIP, who received initial systemic glucocorticoids (median dose
         <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">
          prednisolone
         </a>
         0.54 mg/kg per day) alone, 30 patients (86 percent) responded (&gt;10 percent increase in forced vital capacity [FVC] and diffusing capacity for carbon monoxide [DLCO]) [
         <a href="#rid20">
          20
         </a>
         ]. Seven patients subsequently received cytotoxic agents because of disease progression or glucocorticoid dependence.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A series of 83 patients with idiopathic and rheumatic disease-related NSIP were followed for a mean of 17.4 ±12.1 months; the histopathologic pattern was fibrotic in 72 and cellular in 11 [
         <a href="#rid19">
          19
         </a>
         ]. All but four patients received initial treatment with oral
         <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">
          prednisolone
         </a>
         (approximately 50 mg/day), which led to an improved FVC (defined as &gt;10 percent increase) in 36 (53 percent) and a stable FVC in 19 (28 percent). The extent of disease on HRCT scan appeared to correlate with lung function results.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Among a total of 47 patients from a number of smaller series (both idiopathic and secondary NSIP), treatment with glucocorticoids alone resulted in improvement in 35, stabilization in 6, and deterioration or death in 6 [
         <a href="#rid5">
          5,8,10,11,14
         </a>
         ]. Despite an initial response, some patients subsequently experienced progressive worsening of lung function [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1960919263">
         <span class="h2">
          Pulse methylprednisolone
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with severe NSIP requiring hospitalization, pulse intravenous
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         may be preferred for initial therapy [
         <a href="#rid17">
          17
         </a>
         ]. A typical regimen is 1000 mg/day for three days followed by oral
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         as dosed above (see
         <a class="local">
          'Glucocorticoids'
         </a>
         above). Rarely, patients need additional pulse doses [
         <a href="#rid17">
          17,18
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h2">
          Additional immunosuppressive drugs
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with more severe initial disease or an inadequate response to or intolerance of glucocorticoids, therapy is usually expanded to include an additional immunosuppressive drug, such as
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         or
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         [
         <a href="#rid5">
          5,8,10,11,17,22,23
         </a>
         ]. As these agents have not been assessed in clinical trials of idiopathic NSIP, the optimal choice of which agent to select and what time to initiate therapy is not known.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          Methotrexate
         </a>
         is generally not chosen in idiopathic NSIP because of its potential for pulmonary toxicity. (See
         <a class="medical medical_review" href="/z/d/html/4372.html" rel="external">
          "Methotrexate-induced lung injury"
         </a>
         .)
        </p>
        <p>
         Due to their substantial adverse effects,
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         , calcineurin inhibitors, and
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         are usually reserved for refractory disease that has not responded to
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         in combination with
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         or
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         .
        </p>
        <p>
         No randomized trials have assessed these therapies. All series have included concurrent glucocorticoid therapy. The specific choice of an additional agent varies with the clinical setting.
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h3">
          Azathioprine
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several regimens have been described for initiation of
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         (AZA). A common regimen is to start with 25 to 50 mg/day and increase by 50 mg increments every 7 to 14 days up to 1.5 to 2 mg/kg per day, but not exceeding a maximum total dose of 200 mg/day. A lower dose is indicated in renal insufficiency.
        </p>
        <p>
         The most common side effects of AZA at these doses include gastrointestinal intolerance, bone marrow suppression, and infection. Divided doses may be used to decrease gastrointestinal toxicity. These and other side effects should be discussed with the patient and are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/7994.html" rel="external">
          "Pharmacology and side effects of azathioprine when used in rheumatic diseases"
         </a>
         .)
        </p>
        <p>
         The toxicity of AZA is predominantly related to the activity of thiopurine methyltransferase (TPMT) [
         <a href="#rid24">
          24
         </a>
         ]. Both genotyping and functional assays for this enzyme are now available commercially. Many clinicians perform one test or another before initiating
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         therapy. These issues are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/7994.html" rel="external">
          "Pharmacology and side effects of azathioprine when used in rheumatic diseases", section on 'Pharmacogenetics and azathioprine toxicity'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4058.html" rel="external">
          "Thiopurines: Pretreatment testing and approach to therapeutic drug monitoring for adults with inflammatory bowel disease"
         </a>
         .)
        </p>
        <p>
         AZA has been associated with an increased risk of bacterial and opportunistic infections, but some of the increased risk may be attributable to concomitant glucocorticoid therapy [
         <a href="#rid25">
          25
         </a>
         ]. Based on guidance from the American Thoracic Society, we suggest prophylaxis during combined therapy with
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         ≥20 mg daily and AZA [
         <a href="#rid26">
          26
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1393.html" rel="external">
          "Treatment and prevention of Pneumocystis pneumonia in patients without HIV", section on 'Prophylaxis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3533212014">
         <span class="h3">
          Mycophenolate mofetil
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          Mycophenolate
         </a>
         mofetil (MMF) is an inhibitor of lymphocyte proliferation that is often used in the treatment of systemic rheumatic disease and has shown efficacy in the treatment of interstitial lung disease associated with systemic sclerosis (scleroderma). (See
         <a class="medical medical_review" href="/z/d/html/4375.html" rel="external">
          "Treatment and prognosis of interstitial lung disease in systemic sclerosis (scleroderma)", section on 'Choice of initial agent'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dose and administration
         </strong>
         – The target dose of MMF is generally between 1.5 and 3 g daily, usually in two divided doses (eg, 0.75 to 1.5 twice daily). Starting with lower doses, such as 500 mg twice daily, and increasing to the target dose over three to four months may improve a patient's gastrointestinal tolerance of MMF. Dose adjustments for renal insufficiency and drug interactions are described separately. (See
         <a class="medical medical_review" href="/z/d/html/7990.html" rel="external">
          "Mycophenolate: Overview of use and adverse effects in the treatment of rheumatic diseases"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The optimal duration of MMF therapy for NSIP is unknown.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – In a retrospective study of 56 patients with interstitial pneumonia with autoimmune features (IPAF) and HRCT scans most consistent with NSIP or NSIP with organizing pneumonia, the most common treatment regimen was the combination of glucocorticoids and MMF [
         <a href="#rid27">
          27
         </a>
         ]. Pulmonary physiology was stable and no deaths were reported with this regimen over approximately six years of follow-up.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
         – Gastrointestinal symptoms and dose-related bone marrow suppression are the most commonly observed adverse effects, but these usually resolve with dose adjustments.
         <em>
          Pneumocystis
         </em>
         pneumonia has been described in patients with connective tissue disease taking MMF and glucocorticoids [
         <a href="#rid28">
          28
         </a>
         ]. The indications for PCP prophylaxis are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7990.html" rel="external">
          "Mycophenolate: Overview of use and adverse effects in the treatment of rheumatic diseases", section on 'Adverse effects'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1393.html" rel="external">
          "Treatment and prevention of Pneumocystis pneumonia in patients without HIV", section on 'Prophylaxis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3529048854">
         <span class="h1">
          REFRACTORY DISEASE
         </span>
         <span class="headingEndMark">
          —
         </span>
         A minority of patients have progressive respiratory impairment despite therapy with systemic glucocorticoids and an additional immunosuppressive agent (see
         <a class="local">
          'Additional immunosuppressive drugs'
         </a>
         above). Therapeutic choices for these patients are based on the experience with connective tissue disease-related interstitial lung disease, as randomized trials have not been done in patients with idiopathic NSIP. The antifibrotic agent
         <a class="drug drug_general" data-topicid="97640" href="/z/d/drug information/97640.html" rel="external">
          nintedanib
         </a>
         may be an option for patients with evidence of progressive fibrotic lung disease.
        </p>
        <p class="headingAnchor" id="H557904344">
         <span class="h2">
          Cyclophosphamide
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients who have rapidly progressive initial disease or have progressed despite glucocorticoids and a second line immunosuppressive agent, treatment with
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         (CYC) may have a beneficial effect, based on limited data from case series and clinical experience in lung disease associated with connective tissue diseases (eg, systemic sclerosis). Some authors have used a combination of cyclophosphamide with initial pulse dose glucocorticoids for rapidly progressive initial disease [
         <a href="#rid17">
          17,18
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dose and administration
         </strong>
         – When using CYC for NSIP, we prefer monthly intravenous dosing over daily oral dosing, due to the lower risk of bladder toxicity, based on the protocol used for interstitial lung disease (ILD) in systemic sclerosis. (See
         <a class="medical medical_review" href="/z/d/html/4375.html" rel="external">
          "Treatment and prognosis of interstitial lung disease in systemic sclerosis (scleroderma)", section on 'Cyclophosphamide'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7987.html" rel="external">
          "General toxicity of cyclophosphamide in rheumatic diseases"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The initial dose is based on body surface area (BSA) and adjusted for age, obesity, and renal impairment. Subsequent dosing is based on response to therapy and monitoring of hematologic toxicity.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Adequate hydration should be given prior to and for 24 hours after infusion of CYC to reduce the risk of hemorrhagic cystitis. Mercaptoethane sulfonate (
         <a class="drug drug_general" data-topicid="9615" href="/z/d/drug information/9615.html" rel="external">
          mesna
         </a>
         ), which binds and detoxifies acrolein, may be used to minimize the risk of bladder toxicity, although data in support of using mesna in this setting are limited. (See
         <a class="medical medical_review" href="/z/d/html/7963.html" rel="external">
          "General principles of the use of cyclophosphamide in rheumatic diseases"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A trial of at least three to six months of
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         is needed to ensure an adequate opportunity for clinical response. Because of toxicity with long-term use, cyclophosphamide is usually discontinued after 6 to 12 months or transitioned to a less toxic agent for maintenance.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          Cyclophosphamide
         </a>
         has important hematologic, bladder, and gonadal toxicity. These potential effects should be fully discussed with the patient. CYC has also been reported to be a risk factor for
         <em>
          Pneumocystis
         </em>
         pneumonia, so we suggest administering prophylaxis [
         <a href="#rid29">
          29
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7987.html" rel="external">
          "General toxicity of cyclophosphamide in rheumatic diseases"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1393.html" rel="external">
          "Treatment and prevention of Pneumocystis pneumonia in patients without HIV", section on 'Prophylaxis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy –
         </strong>
         The use of monthly intravenous CYC was
         <strong>
         </strong>
         examined in a series of 54 patients with known or suspected idiopathic NSIP; all but two patients received concomitant
         <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">
          prednisolone
         </a>
         (mean dose 11±5 mg/day) [
         <a href="#rid30">
          30
         </a>
         ]. After six months of CYC, pulmonary function was stable in 25 (46 percent) after previously declining, worsened in six, and led to death in one. A substantial variability in response was noted with a borderline improvement in diffusing capacity for carbon monoxide (DLCO) of 6.8 percent (-74.6 to 92 percent) and a borderline decrease in forced vital capacity (FVC) of -0.5 percent (-22 to 102.2 percent), but broad confidence intervals.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2334409117">
         <span class="h2">
          Rituximab
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          Rituximab
         </a>
         , the chimeric immunoglobulin G1 (IgG1) monoclonal antibody to CD20-positive B cells, has shown mixed results in case series of connective tissue disease-associated interstitial lung disease (CTD-ILD).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dose and administration
         </strong>
         – A variety of
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         dosing regimens have been used; in rheumatic diseases, such as rheumatoid arthritis and polymyositis/dermatomyositis, the trend is to administer two doses of 1 g, intravenously, one or two weeks apart. (See
         <a class="medical medical_review" href="/z/d/html/7501.html" rel="external">
          "Rituximab: Principles of use and adverse effects in rheumatoid arthritis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5133.html" rel="external">
          "Treatment of recurrent and resistant dermatomyositis and polymyositis in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Adverse effects of
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         include infusion reactions, development of antibodies to rituximab, viral and fungal infections, and hypogammaglobulinemia. (See
         <a class="medical medical_review" href="/z/d/html/2811.html" rel="external">
          "Infusion-related reactions to therapeutic monoclonal antibodies used for cancer therapy", section on 'Rituximab'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – Support for the use of
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         in NSIP comes primarily from its use in patients with connective tissue disease-interstitial lung disease (CTD-ILD) and imaging consistent with an NSIP pattern.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In one trial, 122 patients with NSIP pattern on CT (including 37 patients with NSIP, 43 with CT-ILD, and 36 with interstitial pneumonia with autoimmune features) were randomized to
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         and
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         mofetil or mycophenolate mofetil and placebo for six months [
         <a href="#rid31">
          31
         </a>
         ]. Approximately 75 percent of patients had been previously treated with glucocorticoids and 30 percent with other immunosuppressants. Compared with mycophenolate mofetil alone, the addition of rituximab resulted in a 3.6 percent improvement in FVC (95% CI 0.4-6.8) and improved progression free survival at six months, although other clinical outcomes were not changed. Infectious complications were more common in the rituximab group.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a series of 24 patients with CTD-ILD (mostly associated with rheumatoid arthritis) and a pattern consistent with NSIP on HRCT, the response to
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         was variable, but overall rituximab did not have a glucocorticoid-sparing effect [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a separate series, 24 patients with CTD-ILD were treated with
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         because of continued decline in pulmonary function with other immunosuppressive agents [
         <a href="#rid33">
          33
         </a>
         ]. After rituximab, FVC improved or stabilized (mean change 4.1 percent, 95% CI 0.9-7.2). Imaging showed improvement or stability in 11 patients and deterioration in 9. Four patients with antisynthetase syndrome experienced improvement in FVC &gt;10 percent.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A series of 10 patients with systemic sclerosis-ILD experienced a 19 percent improvement in DLCO and a 13 percent increase in FVC [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3113769044">
         <span class="h2">
          Calcineurin inhibitors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Data on the use of the calcineurin inhibitors,
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         and
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         , for NSIP are limited to observational series. Until more data are available, use of cyclosporine and tacrolimus is generally reserved for refractory disease.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dose and administration
         </strong>
         – The dose and target trough levels of calcineurin inhibitors vary with the disease being treated.
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          Cyclosporine
         </a>
         and
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         should be administered at a consistent time of day. In a series of patients with acute interstitial pneumonia, the dose of cyclosporine was 50 to 200 mg/day, trough level 100 to 150 ng/mL [
         <a href="#rid23">
          23
         </a>
         ]. In a study of interstitial lung disease associated with polymyositis/dermatomyositis (PM/DM), cyclosporine was titrated to a trough level of 150 ng/mL and two hour peak level of 1000 ng/mL [
         <a href="#rid35">
          35
         </a>
         ]. For tacrolimus, a starting dose of 1 to 3 mg/day, targeting a trough level of 5 to 20 ng/mL, has been reported [
         <a href="#rid35">
          35,36
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7995.html" rel="external">
          "Pharmacology of cyclosporine and tacrolimus"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – Limited data on the efficacy of
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         and
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         in NSIP come from small case series.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In two small observational series, the addition of
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         led to stabilization or clinical improvement in seven of nine patients who had not responded to
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         alone and one patient who was refractory to both prednisone and
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         [
         <a href="#rid8">
          8,23
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          Tacrolimus
         </a>
         was associated with longer progression-free survival compared with conventional therapy in patients with interstitial lung disease due to polymyositis/dermatomyositis [
         <a href="#rid36">
          36
         </a>
         ], but use of tacrolimus for idiopathic NSIP has not been reported.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1184399264">
         <span class="h2">
          Nintedanib
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="97640" href="/z/d/drug information/97640.html" rel="external">
          Nintedanib
         </a>
         may reduce the rate of disease progression in patients with idiopathic NSIP who develop progressive fibrosis. Nintedanib has been approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for use in patients with idiopathic pulmonary fibrosis (IPF), systemic sclerosis-interstitial lung disease (SSc-ILD), and progressive chronic fibrosing ILD of other origin (eg, rheumatoid arthritis, fibrotic hypersensitivity pneumonitis) [
         <a href="#rid37">
          37
         </a>
         ]. The role of nintedanib in NSIP remains ill-defined, as much of the supportive evidence is indirect and the impact on patient-important outcomes is uncertain. (See
         <a class="medical medical_review" href="/z/d/html/4328.html" rel="external">
          "Treatment of idiopathic pulmonary fibrosis", section on 'Nintedanib'
         </a>
         .)
        </p>
        <p>
         The benefit of
         <a class="drug drug_general" data-topicid="97640" href="/z/d/drug information/97640.html" rel="external">
          nintedanib
         </a>
         in progressive chronic fibrosing ILD was demonstrated in a randomized trial that included 663 patients with various fibrotic interstitial lung diseases affecting at least 10 percent of the lung on high-resolution computed tomography (HRCT) [
         <a href="#rid38">
          38
         </a>
         ]. Additionally, participants met at least one of these three criteria in the preceding two years: a decrease in FVC of at least 10 percent of predicted value, a decrease in FVC of 5 to 10 percent of predicted value with worsening symptoms and/or increased extent of HRCT fibrosis; or worsening symptoms and increased extent of HRCT fibrosis. After 52 weeks, nintedanib slowed the overall adjusted rate of decline in FVC with a between-group difference of 107 mL/year (95% CI 65.4 to 148.5). In a subgroup analysis of the effects of nintedanib versus placebo on reducing the rate of FVC decline, it was shown that patients with idiopathic NSIP had a between-group difference of 142 mL/year (95% CI 46-237) [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
         Dosing, administration, and monitoring considerations for
         <a class="drug drug_general" data-topicid="97640" href="/z/d/drug information/97640.html" rel="external">
          nintedanib
         </a>
         administration are described in more detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/4328.html" rel="external">
          "Treatment of idiopathic pulmonary fibrosis", section on 'Nintedanib'
         </a>
         .)
        </p>
        <p>
         Additional details of investigations and treatments for patients with progressive fibrotic interstitial lung disease are discussed elsewhere.
        </p>
        <p class="headingAnchor" id="H3383197799">
         <span class="h1">
          ONGOING MONITORING
         </span>
         <span class="headingEndMark">
          —
         </span>
         The response to therapy should be assessed at one month, and then at three to six month intervals, or sooner, if the patient has more severe initial disease or reports worsening symptoms.
        </p>
        <p>
         We monitor respiratory symptoms (eg, dyspnea, exercise tolerance, cough), development of extrapulmonary symptoms suggestive of connective tissue disease, and pulmonary function tests (eg, spirometry, diffusing capacity for carbon monoxide, oximetry, six-minute walk test) [
         <a href="#rid40">
          40,41
         </a>
         ]. Interval high resolution computed tomography (HRCT) is performed when changes in the clinical assessment and/or pulmonary function tests suggest worsening disease or an intercurrent process. (See
         <a class="medical medical_review" href="/z/d/html/6969.html" rel="external">
          "Overview of pulmonary function testing in adults"
         </a>
         .)
        </p>
        <p>
         For patients with more severe disease or a sudden decrease in exercise tolerance, we assess for development of pulmonary hypertension, thromboembolic disease, infection, and other comorbid diseases (eg, heart failure, muscle weakness).
        </p>
        <p>
         For patients on immunosuppressive therapy, monitoring includes assessment for drug-related adverse effects, such as bone marrow suppression, impaired renal function, and liver inflammation, and depends on the specific agent(s) being used. Most patients on glucocorticoids plus additional immunosuppressive agent will be candidates for
         <em>
          Pneumocystis jirovecii
         </em>
         prophylaxis. (See
         <a class="medical medical_review" href="/z/d/html/1393.html" rel="external">
          "Treatment and prevention of Pneumocystis pneumonia in patients without HIV", section on 'Prophylaxis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1463163570">
         <span class="h2">
          Acute exacerbations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acute exacerbations, similar to those seen in idiopathic pulmonary fibrosis, can occasionally complicate the course of NSIP. While the diagnosis and management of acute exacerbations have not been specifically described for NSIP, we manage these patients similarly to acute exacerbations of IPF, pending NSIP-specific guidance. (See
         <a class="medical medical_review" href="/z/d/html/110885.html" rel="external">
          "Acute exacerbations of idiopathic pulmonary fibrosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2106300130">
         <span class="h1">
          LUNG TRANSPLANTATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with severe NSIP that is progressive and disabling despite immunosuppressive therapy may be considered for lung transplantation [
         <a href="#rid42">
          42
         </a>
         ]. Between 2004 and 2015, 189 patients with idiopathic NSIP underwent lung transplantation according to the International Society for Heart and Lung Transplantation [
         <a href="#rid43">
          43
         </a>
         ]. Patients with interstitial lung disease have a median survival after lung transplantation of 4.8 years, which is slightly less than the median survival of 5.6 years for patients with COPD [
         <a href="#rid43">
          43
         </a>
         ]. The indications for lung transplantation for NSIP are similar to those for other interstitial lung diseases. (See
         <a class="medical medical_review" href="/z/d/html/4658.html" rel="external">
          "Lung transplantation: General guidelines for recipient selection"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4328.html" rel="external">
          "Treatment of idiopathic pulmonary fibrosis", section on 'Indications and choice of procedure'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The overall prognosis and response to therapy for idiopathic NSIP is favorable compared to idiopathic pulmonary fibrosis/usual interstitial pneumonitis (IPF/UIP) [
         <a href="#rid1">
          1,13,44
         </a>
         ], although substantial heterogeneity is noted [
         <a href="#rid1">
          1
         </a>
         ]. Approximately two-thirds of treated patients with idiopathic NSIP are stable or improved in long-term follow-up, but a 15 to 26 percent mortality at five years is noted [
         <a href="#rid1">
          1,8,19,45
         </a>
         ].
        </p>
        <p>
         The prognosis of histopathologic NSIP appears to be influenced by the underlying cause. In a retrospective study, survival was similar for NSIP associated with undifferentiated connective tissue disease (UCTD) and known CTD and better for UCTD-NSIP than for idiopathic NSIP (p = 0.02) [
         <a href="#rid46">
          46
         </a>
         ]. A pattern of NSIP with an overall clinical diagnosis of chronic hypersensitivity pneumonitis was an independent predictor of mortality (hazard ratio 2.17, 95% CI 1.05–4.47).
        </p>
        <p>
         The results on serial pulmonary function testing may be a better prognostic indicator than baseline histopathology [
         <a href="#rid47">
          47-49
         </a>
         ]. In a series of patients with IPF/UIP (n = 61) and NSIP (n = 43), the patients with NSIP had a longer median survival than those with UIP/IPF (56 versus 33 months), but this difference did not appear until after two years of follow-up [
         <a href="#rid47">
          47
         </a>
         ]. Histopathology (UIP versus NSIP) predicted prognosis as a baseline factor and at six months when changes in pulmonary physiology were examined. After 12 months of follow-up, performance on pulmonary function tests predicted subsequent mortality while histopathology was no longer predictive. Change in diffusing capacity for carbon monoxide (DLCO) was the strongest determinant of mortality at 12 months of follow-up.
        </p>
        <p class="headingAnchor" id="H3241816503">
         <span class="h1">
          FUTURE DIRECTIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The antifibrotic agents
         <a class="drug drug_general" data-topicid="88424" href="/z/d/drug information/88424.html" rel="external">
          pirfenidone
         </a>
         and
         <a class="drug drug_general" data-topicid="97640" href="/z/d/drug information/97640.html" rel="external">
          nintedanib
         </a>
         slow disease progression in idiopathic pulmonary fibrosis (IPF), raising the possibility that they might be beneficial in patients with progressive fibrotic NSIP [
         <a href="#rid38">
          38,50
         </a>
         ]. Further study is needed to determine the efficacy of pirfenidone and nintedanib in progressive fibrotic NSIP and to clarify the patients most likely to benefit. (See
         <a class="local">
          'Nintedanib'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/4328.html" rel="external">
          "Treatment of idiopathic pulmonary fibrosis", section on 'Medical therapies'
         </a>
         .).
        </p>
        <p class="headingAnchor" id="H1824543504">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/118793.html" rel="external">
          "Society guideline links: Interstitial lung disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H25">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Overview
         </strong>
         – The treatment of nonspecific interstitial pneumonia (NSIP) depends on the cause, disease severity, and rate of progression. While the discussion in the sections that follow will emphasize the treatment for idiopathic NSIP, much of the support for treatment selections is based on experience in connective tissue-associated NSIP. (See
         <a class="local">
          'Overview of treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In terms of supportive care, current smokers should be strongly advised to stop smoking; pneumococcal, coronavirus 2019 (COVID-19), and seasonal influenza vaccination should be offered as appropriate. (See
         <a class="local">
          'Supportive care'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Avoidance of contributory exposures
         </strong>
         – Patients with exposure to potential culprit drugs (eg,
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         ,
         <a class="drug drug_general" data-topicid="9704" href="/z/d/drug information/9704.html" rel="external">
          nitrofurantoin
         </a>
         , statins) or inhalational agents (eg, organic dusts) should avoid further exposure. This alone may be adequate treatment. (See
         <a class="local">
          'Overview of treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Observation for mild disease
         </strong>
         – Patients who have mild disease based on minimal symptoms and near normal pulmonary function may be observed for a period of time without treatment. Symptoms and pulmonary function should be reassessed every three to six months, and therapy initiated if there is progression. (See
         <a class="local">
          'Observation for mild stable disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Glucocorticoids for moderate to severe disease
         </strong>
         – For the majority of patients with moderate to severe NSIP or with mild disease that has progressed, we suggest initial treatment with systemic glucocorticoids (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). The usual regimen is the equivalent of oral
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         1 mg/kg (eg, 40 to 60 mg/day) per day for the first month. Initial pulse
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         may be used for more severe disease. For patients who respond, prednisone is gradually tapered, as tolerated, to 5 to 10 mg daily or on alternate days by the end of 6 to 9 months with attempted cessation after one year. (See
         <a class="local">
          'Initial therapy for moderate to severe disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          More severe or worsening disease
         </strong>
         – For patients with more severe disease at presentation, worsening lung function despite glucocorticoids, or inability to taper glucocorticoids, we suggest addition of another immunosuppressive agent (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ), such as
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         or
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         ; data are insufficient to guide selection between these. Calcineurin inhibitors are a rarely used alternative. (See
         <a class="local">
          'Additional immunosuppressive drugs'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Refractory disease
         </strong>
         – For patients who do not respond to the combination of glucocorticoid therapy and
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         or
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         , changing the immunosuppressive agent to
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         , or a calcineurin inhibitor may be beneficial, although data are limited. (See
         <a class="local">
          'Refractory disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="97640" href="/z/d/drug information/97640.html" rel="external">
          Nintedanib
         </a>
         may decrease lung function decline in patients with NSIP that meets criteria for progressive chronic fibrosing ILD. (See
         <a class="local">
          'Refractory disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Monitoring
         </strong>
         – The response to therapy should be assessed at one month, and then at three to six month intervals, or sooner, if the patient reports worsening symptoms. Assessment usually includes symptoms (eg, dyspnea, exercise tolerance, cough), physical examination, spirometry, lung volumes, diffusing capacity for carbon monoxide (DLCO), and six-minute walk testing with oximetry. Interval high resolution computed tomography (HRCT) is performed less often, depending on changes in the clinical assessment and pulmonary function tests. (See
         <a class="local">
          'Ongoing monitoring'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           Pneumocystis
          </em>
         </strong>
         <strong>
          prophylaxis
         </strong>
         – We suggest
         <em>
          Pneumocystis
         </em>
         prophylaxis for any patient with NSIP receiving moderate to high dose glucocorticoid (≥20 mg per day) and a second immunosuppressive agent (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Some experts also administer
         <em>
          Pneumocystis
         </em>
         prophylaxis to patients on monotherapy with moderate to high dose glucocorticoids. (See
         <a class="medical medical_review" href="/z/d/html/1393.html" rel="external">
          "Treatment and prevention of Pneumocystis pneumonia in patients without HIV", section on 'Prophylaxis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">
          "Major adverse effects of systemic glucocorticoids"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lung transplantation
         </strong>
         – Rarely, patients will develop advanced lung disease despite immunosuppressive therapy and are potential candidates for lung transplantation. (See
         <a class="local">
          'Lung transplantation'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/4658.html" rel="external">
          "Lung transplantation: General guidelines for recipient selection"
         </a>
         .)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013; 188:733.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sattler F, Nichols L, Hirano L, et al. Nonspecific interstitial pneumonitis mimicking Pneumocystis carinii pneumonia. Am J Respir Crit Care Med 1997; 156:912.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Duggal L, Puri V, Vasdev N. Non-specific interstitial pneumonia in an HIV positive patient. J Assoc Physicians India 2005; 53:564.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           George MP, Singh V, Gladwin MT. Noninfectious and Nonneoplastic Conditions Associated with Human Immunodeficiency Virus Infection. Semin Respir Crit Care Med 2016; 37:289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nagai S, Kitaichi M, Itoh H, et al. Idiopathic nonspecific interstitial pneumonia/fibrosis: comparison with idiopathic pulmonary fibrosis and BOOP. Eur Respir J 1998; 12:1010.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Belloli EA, Beckford R, Hadley R, Flaherty KR. Idiopathic non-specific interstitial pneumonia. Respirology 2016; 21:259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bradley B, Branley HM, Egan JJ, et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 2008; 63 Suppl 5:v1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daniil ZD, Gilchrist FC, Nicholson AG, et al. A histologic pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 1999; 160:899.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Katzenstein AL, Fiorelli RF. Nonspecific interstitial pneumonia/fibrosis. Histologic features and clinical significance. Am J Surg Pathol 1994; 18:136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cottin V, Donsbeck AV, Revel D, et al. Nonspecific interstitial pneumonia. Individualization of a clinicopathologic entity in a series of 12 patients. Am J Respir Crit Care Med 1998; 158:1286.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fujita J, Yamadori I, Suemitsu I, et al. Clinical features of non-specific interstitial pneumonia. Respir Med 1999; 93:113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miki H, Mio T, Nagai S, et al. Fibroblast contractility: usual interstitial pneumonia and nonspecific interstitial pneumonia. Am J Respir Crit Care Med 2000; 162:2259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Travis WD, Matsui K, Moss J, Ferrans VJ. Idiopathic nonspecific interstitial pneumonia: prognostic significance of cellular and fibrosing patterns: survival comparison with usual interstitial pneumonia and desquamative interstitial pneumonia. Am J Surg Pathol 2000; 24:19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flaherty KR, Toews GB, Travis WD, et al. Clinical significance of histological classification of idiopathic interstitial pneumonia. Eur Respir J 2002; 19:275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bjoraker JA, Ryu JH, Edwin MK, et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998; 157:199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nicholson AG, Colby TV, du Bois RM, et al. The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 2000; 162:2213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kondoh Y, Taniguchi H, Yokoi T, et al. Cyclophosphamide and low-dose prednisolone in idiopathic pulmonary fibrosis and fibrosing nonspecific interstitial pneumonia. Eur Respir J 2005; 25:528.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nanki N, Fujita J, Yamaji Y, et al. Nonspecific interstitial pneumonia/fibrosis completely recovered by adding cyclophosphamide to corticosteroids. Intern Med 2002; 41:867.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park IN, Jegal Y, Kim DS, et al. Clinical course and lung function change of idiopathic nonspecific interstitial pneumonia. Eur Respir J 2009; 33:68.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee JY, Jin SM, Lee BJ, et al. Treatment response and long term follow-up results of nonspecific interstitial pneumonia. J Korean Med Sci 2012; 27:661.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flaherty KR, Toews GB, Lynch JP 3rd, et al. Steroids in idiopathic pulmonary fibrosis: a prospective assessment of adverse reactions, response to therapy, and survival. Am J Med 2001; 110:278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Douglas WW, Tazelaar HD, Hartman TE, et al. Polymyositis-dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med 2001; 164:1182.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Homma S, Sakamoto S, Kawabata M, et al. Cyclosporin treatment in steroid-resistant and acutely exacerbated interstitial pneumonia. Intern Med 2005; 44:1144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bakker JA, Drent M, Bierau J. Relevance of pharmacogenetic aspects of mercaptopurine metabolism in the treatment of interstitial lung disease. Curr Opin Pulm Med 2007; 13:458.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ginzler E, Diamond H, Kaplan D, et al. Computer analysis of factors influencing frequency of infection in systemic lupus erythematosus. Arthritis Rheum 1978; 21:37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Limper AH, Knox KS, Sarosi GA, et al. An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med 2011; 183:96.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chartrand S, Swigris JJ, Stanchev L, et al. Clinical features and natural history of interstitial pneumonia with autoimmune features: A single center experience. Respir Med 2016; 119:150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang Y, Zheng Y. Pneumocystis jirovecii pneumonia in mycophenolate mofetil-treated patients with connective tissue disease: analysis of 17 cases. Rheumatol Int 2014; 34:1765.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arend SM, Kroon FP, van't Wout JW. Pneumocystis carinii pneumonia in patients without AIDS, 1980 through 1993. An analysis of 78 cases. Arch Intern Med 1995; 155:2436.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Corte TJ, Ellis R, Renzoni EA, et al. Use of intravenous cyclophosphamide in known or suspected, advanced non-specific interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis 2009; 26:132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mankikian J, Caille A, Reynaud-Gaubert M, et al. Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial. Eur Respir J 2023; 61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chartrand S, Swigris JJ, Peykova L, Fischer A. Rituximab for the treatment of connective tissue disease-associated interstitial lung disease. Sarcoidosis Vasc Diffuse Lung Dis 2016; 32:296.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sharp C, McCabe M, Dodds N, et al. Rituximab in autoimmune connective tissue disease-associated interstitial lung disease. Rheumatology (Oxford) 2016; 55:1318.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fitzgerald DB, Moloney F, Twomey M, et al. Efficacy and Safety of Rituximab in Connective Tissue Disease related Interstitial Lung Disease. Sarcoidosis Vasc Diffuse Lung Dis 2015; 32:215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kurita T, Yasuda S, Amengual O, Atsumi T. The efficacy of calcineurin inhibitors for the treatment of interstitial lung disease associated with polymyositis/dermatomyositis. Lupus 2015; 24:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kurita T, Yasuda S, Oba K, et al. The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis. Rheumatology (Oxford) 2015; 54:39.
          </a>
         </li>
         <li class="breakAll">
          Prescribing information for nintedanib. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/205832s013lbl.pdf (Accessed on November 29, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med 2019; 381:1718.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wells AU, Flaherty KR, Brown KK, et al. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med 2020; 8:453.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lama VN, Flaherty KR, Toews GB, et al. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003; 168:1084.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           du Bois RM, Weycker D, Albera C, et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med 2011; 184:1382.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weill D, Benden C, Corris PA, et al. A consensus document for the selection of lung transplant candidates: 2014--an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2015; 34:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yusen RD, Edwards LB, Dipchand AI, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-third Adult Lung and Heart-Lung Transplant Report-2016; Focus Theme: Primary Diagnostic Indications for Transplant. J Heart Lung Transplant 2016; 35:1170.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Travis WD, Hunninghake G, King TE Jr, et al. Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project. Am J Respir Crit Care Med 2008; 177:1338.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002; 165:277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nunes H, Schubel K, Piver D, et al. Nonspecific interstitial pneumonia: survival is influenced by the underlying cause. Eur Respir J 2015; 45:746.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Latsi PI, du Bois RM, Nicholson AG, et al. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 2003; 168:531.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jegal Y, Kim DS, Shim TS, et al. Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. Am J Respir Crit Care Med 2005; 171:639.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flaherty KR, Mumford JA, Murray S, et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003; 168:543.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maher TM, Corte TJ, Fischer A, et al. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med 2020; 8:147.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 4306 Version 31.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24032382" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9310013" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Nonspecific interstitial pneumonitis mimicking Pneumocystis carinii pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16121814" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Non-specific interstitial pneumonia in an HIV positive patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26974305" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Noninfectious and Nonneoplastic Conditions Associated with Human Immunodeficiency Virus Infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9863989" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Idiopathic nonspecific interstitial pneumonia/fibrosis: comparison with idiopathic pulmonary fibrosis and BOOP.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26564810" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Idiopathic non-specific interstitial pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18757459" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10471616" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : A histologic pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8291652" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Nonspecific interstitial pneumonia/fibrosis. Histologic features and clinical significance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9769293" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Nonspecific interstitial pneumonia. Individualization of a clinicopathologic entity in a series of 12 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10464862" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Clinical features of non-specific interstitial pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11112149" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Fibroblast contractility: usual interstitial pneumonia and nonspecific interstitial pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10632484" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Idiopathic nonspecific interstitial pneumonia: prognostic significance of cellular and fibrosing patterns: survival comparison with usual interstitial pneumonia and desquamative interstitial pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11866008" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Clinical significance of histological classification of idiopathic interstitial pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9445300" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11112140" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15738299" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Cyclophosphamide and low-dose prednisolone in idiopathic pulmonary fibrosis and fibrosing nonspecific interstitial pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12413012" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Nonspecific interstitial pneumonia/fibrosis completely recovered by adding cyclophosphamide to corticosteroids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18829672" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Clinical course and lung function change of idiopathic nonspecific interstitial pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22690098" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Treatment response and long term follow-up results of nonspecific interstitial pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11239846" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Steroids in idiopathic pulmonary fibrosis: a prospective assessment of adverse reactions, response to therapy, and survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11673206" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Polymyositis-dermatomyositis-associated interstitial lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16357451" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Cyclosporin treatment in steroid-resistant and acutely exacerbated interstitial pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17940494" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Relevance of pharmacogenetic aspects of mercaptopurine metabolism in the treatment of interstitial lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/414759" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Computer analysis of factors influencing frequency of infection in systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21193785" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27692137" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Clinical features and natural history of interstitial pneumonia with autoimmune features: A single center experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24948376" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Pneumocystis jirovecii pneumonia in mycophenolate mofetil-treated patients with connective tissue disease: analysis of 17 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7503602" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Pneumocystis carinii pneumonia in patients without AIDS, 1980 through 1993. An analysis of 78 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20560293" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Use of intravenous cyclophosphamide in known or suspected, advanced non-specific interstitial pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37230499" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26847096" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Rituximab for the treatment of connective tissue disease-associated interstitial lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27060110" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Rituximab in autoimmune connective tissue disease-associated interstitial lung disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26422566" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Efficacy and Safety of Rituximab in Connective Tissue Disease related Interstitial Lung Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25297551" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : The efficacy of calcineurin inhibitors for the treatment of interstitial lung disease associated with polymyositis/dermatomyositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24764266" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24764266" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31566307" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32145830" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12917227" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21940789" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25085497" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : A consensus document for the selection of lung transplant candidates: 2014--an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27772669" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : The Registry of the International Society for Heart and Lung Transplantation: Thirty-third Adult Lung and Heart-Lung Transplant Report-2016; Focus Theme: Primary Diagnostic Indications for Transplant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18388353" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11790668" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25537566" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Nonspecific interstitial pneumonia: survival is influenced by the underlying cause.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12791580" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15640368" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12773329" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31578169" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
